Overcoming HIV-1 resistance to protease inhibitors

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 2, 2006, Pages 281-286

  Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; GLUCOSE TRANSPORTER 4; INDINAVIR; KNI 577; KNI 764; KYNOSTATIN 272; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BINDING AFFINITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENTHALPY; ENTROPY; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MUTATIONAL ANALYSIS; REVIEW; THERMODYNAMICS; VIRUS MUTANT; VIRUS MUTATION; WILD TYPE;

EID: 33748514992     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.06.005     Document Type: Review

References (34)

1. Ho D.D., et al. Characterization of human immunodeficiency virus type 1 variants with increased resistant to a C2-symmetric protease inhibitor. J. Virol. 68 (1994) 2016-2020
2. Kaplan A.H., et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. U S A 91 (1994) 5597-5601
3. Condra J.H., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
4. Roberts N.A. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9 (1995) S27-S32
5. Hong L., et al. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry 35 (1996) 10627-10633
6. Ala P.J., et al. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36 (1997) 1573-1580
7. Jadhav P.K., et al. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40 (1997) 181-191
8. Todd M.J., et al. The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 39 (2000) 11876-11883
9. Ohtaka H., et al. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11 (2002) 1908-1916
10. Muzammil S., et al. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42 (2003) 631-638
11. Velazquez-Campoy A., et al. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. 3 (2003) 311-328
12. Ohtaka H., et al. Multidrug-resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 42 (2003) 13659-13666
13. Rusconi S., et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. 44 (2000) 1328-1332
14. Feher A., et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur. J. Biochem. 269 (2002) 4114-4120
15. In: Gulnik S., et al. (Ed). HIV protease: enzyme function and drug resistance (1999), Academic Press
16. Kozal M.J., et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2 (1996) 753-759
17. Shafer R.W., et al. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type I seroconverters in Zimbawe. AIDS Res. Hum. Retroviruses 15 (1999) 65-69
18. Boden D., and Markowitz M. Resistance to immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42 (1998) 2775-2783
19. Hertogs K., et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14 (2000) 1203-1210
20. Erickson J.W., and Burt S.K. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 545-571
21. Olsen D.B., et al. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J. Biol. Chem. 274 (1999) 23699-23701
22. Velazquez-Campoy A., et al. The binding energetics of first and second generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochim. Biophys. 390 (2001) 169-175
23. Ohtaka H., and Freire E. Adaptive inhibitors of the HIV-1 protease. Progr. Biophys. Mol. Biol. 88 (2005) 193-208
24. Muzammil S., et al. Unique response of tipranavir to multi-drug resistant HIV-1 proteases suggests new ways of combating drug resistance. Antivir. Ther. 10 (2005) S70
25. Freire E. Isothermal titration calorimetry: controlling binding forces in lead optimization. Drug Discov. Today 1 (2005) 295-299
26. Murata H., et al. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr. Drug Targets Infect. Disord. 2 (2002) 1-8
27. Wang S., et al. Association of HIV-protease inhibitors with insulin resistance is related to potency of inhibition of GLUT4 and GLUT1 activity in adipocytes and myocytes. Antivir. Ther. 8 (2003) L36
28. Hertel J., et al. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J. Biol. Chem. 279 (2004) 55147-55152
29. Freire E. Designing drugs against heterogeneous targets. Nat. Biotechnol. 20 (2002) 15-16
30. Vega S., et al. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins 55 (2004) 594-602
31. Velazquez-Campoy A., et al. Amplification of the effects of drug-resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 41 (2002) 8613-8619
32. Velazquez-Campoy A., et al. Protease inhibition in African subtypes of HIV-1. AIDS Rev. 5 (2003) 165-171
33. Velazquez-Campoy A., et al. Thermodynamic dissection of the binding energetics of KNI-272, a powerful HIV-1 protease inhibitor. Protein Sci. 9 (2000) 1801-1809
34. Velazquez-Campoy A., and Freire E. Incorporating target heterogeneity in drug design. J. Cell. Biochem. S37 (2001) 82-88